SWMR vs VYGR
SWMR: Swarmer Inc is an early-stage company currently working to develop and commercialize its products while managing significant operating losses and high customer concentration. VYGR: A gene therapy company developing AAV-based therapeutics and non-viral treatments for neurological diseases, relying heavily on partnership revenue while advancing early-stage clinical programs.
Side-by-side fundamentals
| Metric | SWMR | VYGR | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $40.06 | $3.09 | |
| Market cap as of 2026-07-30 | $449M | $187M | |
| PEG as of 2026-07-30 | n/a | -0.04 | |
| Net margin as of 2026-07-30 | -2752.3% | -319.6% | VYGR higher |
| Gross margin as of 2026-07-30 | +41.2% | n/a | |
| Operating margin as of 2026-07-30 | -1650.9% | -349.2% | VYGR higher |
| ROE as of 2026-07-30 | -94.0% | -56.0% | VYGR higher |
| ROA as of 2026-07-30 | -82.5% | -43.1% | VYGR higher |
| Debt / equity as of 2026-07-30 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-30 | n/a | -45.5% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -0.4% | |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-07-30 | 1.21 | 1.33 | |
| 1-year return as of 2026-07-27 close | n/a | -4.6% |
Fundamentals: market data, as of 2026-07-30. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.